| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/10/2007 | EP1740224A2 Compositions as adjuvants to improve immune responses to vaccines and methods of use |
| 01/10/2007 | EP1740212A2 Pharmaceutical compositions comprising beta-carboline derivatives and use thereof for the treatment of cancer |
| 01/10/2007 | EP1740211A2 Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists |
| 01/10/2007 | EP1740196A1 Compositions and method for alleviating inflammation and oxidative stress in a mammal |
| 01/10/2007 | EP1740182A2 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer |
| 01/10/2007 | EP1740181A1 New pharmaceutical compositions for the treatment of sexual disorders ii |
| 01/10/2007 | EP1740170A2 Combination therapy with azd2171 and platinum anti-tumour agent |
| 01/10/2007 | EP1521583B1 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo (2,1-b)-quinazolinone derivatives |
| 01/10/2007 | EP1416885B1 Devices for delivery of therapeutic agents with variable release profile |
| 01/10/2007 | EP1355916B1 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| 01/10/2007 | EP1335687B1 Method for restoring a damaged or degenerated intervertebral disc |
| 01/10/2007 | EP1305051A4 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer |
| 01/10/2007 | EP1244447B1 Novel methods and compositions involving opioids and antagonists thereof |
| 01/10/2007 | EP1232180B1 Polypeptides derived from vitamin d nuclear receptor, and their uses in particular for screening vitamin d analogues |
| 01/10/2007 | EP1218011B1 Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes, dna viruses and retroviruses |
| 01/10/2007 | EP1200073B1 SELECTIVE iGluR 5? RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
| 01/10/2007 | EP1129213B1 Bacillus strain and assay methods |
| 01/10/2007 | EP1078060B1 Antibodies to dendritic cells and human dendritic cell populations and uses thereof |
| 01/10/2007 | EP1035856B1 Isolated dna encoding human h3 histamine receptor |
| 01/10/2007 | EP1017723B1 Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use |
| 01/10/2007 | EP0794793B1 Composition for prevention and treatment of hiv-1 infection comprising at least two different hiv-1 reverse transcriptase inhibitors |
| 01/10/2007 | CN1894344A Compounds for dual photodiagnosis and therapy |
| 01/10/2007 | CN1893979A Remedy for angitis |
| 01/10/2007 | CN1893978A Combinations for HCV treatment |
| 01/10/2007 | CN1893977A Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient. |
| 01/10/2007 | CN1893955A Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| 01/10/2007 | CN1893950A Methods of treating acute inflammation in animals with p38 map kinase inhibitors |
| 01/10/2007 | CN1893947A Use of siramesine in the treatment of cancer |
| 01/10/2007 | CN1893946A Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity |
| 01/10/2007 | CN1893935A The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist |
| 01/10/2007 | CN1893934A Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases |
| 01/10/2007 | CN1893923A Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
| 01/10/2007 | CN1893920A Effervescent preparation of a basic medicinally active substance |
| 01/10/2007 | CN1891298A Drug depot for parenteral drug release, in particular intravascular drug release |
| 01/10/2007 | CN1891297A Medicinal composition containing angiotensin II receptor agonist and fibric acid compound |
| 01/10/2007 | CN1891296A Medicinal composition containing calcium agonist and phenoxy acid compound |
| 01/10/2007 | CN1891221A Combination therapy to treat hepatitis b virus |
| 01/10/2007 | CN1294142C 17 beta-carbothioate 17 alpha-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| 01/10/2007 | CN1294141C 6 alpha., 9 alpha-difluoro-17.alpha.-[(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent |
| 01/10/2007 | CN1293878C Preventing or therapeutic agent for eye fatigue and pseudomyopia |
| 01/10/2007 | CN1293876C New use of 1,3-propylene glycol derivative |
| 01/10/2007 | CN1293867C Medicinal compound preparation |
| 01/09/2007 | US7160982 Peptide substrate identified by type BoNT/B botulinus toxin and use thereof for assaying and/or detecting said toxin or corresponding inhibitors |
| 01/09/2007 | US7160920 Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
| 01/09/2007 | US7160908 Platinum amine glycine complex derivatives; antiproliferative and antitumor agents; side effect reduction; reversibly active; on and off |
| 01/09/2007 | US7160904 Nicotine in therapeutic angiogenesis and vasculogenesis |
| 01/09/2007 | US7160899 Use of at least one compound with neurotrophic activity and at least one adenosine A2A receptor antagonist for the manufacture of a medicament for the treatment, prevention or alleviation of Parkinson's disease in a subject |
| 01/09/2007 | US7160898 Pharmacological treatment for sleep apnea |
| 01/09/2007 | US7160895 Inhibiting the proliferation of tumor cells, using 6-chloro-1,9-dimethyl-3-phenyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; anticancer treatment |
| 01/09/2007 | US7160870 Thrombopoietin mimetics |
| 01/09/2007 | US7160861 Methods of inducing IL-10 production |
| 01/09/2007 | US7160856 Such as alpha-O-linked glycopeptides with clustered glycodomains which are useful as anticancer agents |
| 01/09/2007 | US7160684 Methods of selecting compounds for modulation of bladder function |
| 01/09/2007 | US7160549 including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter |
| 01/09/2007 | US7160541 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 01/09/2007 | CA2400801C Treatment of congestive heart failure by pretreated autologous blood |
| 01/09/2007 | CA2344248C 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors |
| 01/09/2007 | CA2340056C Pharmaceutical compositions containing lipase inhibitors |
| 01/09/2007 | CA2333427C Foaming composition for hair care |
| 01/09/2007 | CA2295177C Drug targeting system, method of its preparation and its use |
| 01/09/2007 | CA2251702C Biologically active composition |
| 01/09/2007 | CA2194352C Diagnostic methods and compositions relating to the proteoglycan proteins of cartilage breakdown |
| 01/09/2007 | CA2186844C Use of serotonin antagonists (5ht3) for treating fibromyalgia |
| 01/09/2007 | CA2180296C Treatment of arteriosclerosis and xanthoma |
| 01/09/2007 | CA2142126C Inhalation powder containing antistatic agent |
| 01/08/2007 | WO2007007686A1 Composition for prevention of occurrence of cardiovascular event |
| 01/04/2007 | WO2007002910A1 Quadraphasic continuous graduated estrogen contraceptive |
| 01/04/2007 | WO2007001066A1 Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker |
| 01/04/2007 | WO2007001058A1 Herpesvirus-derived therapeutic agent for pain |
| 01/04/2007 | WO2007000970A1 Therapeutic agent for pain |
| 01/04/2007 | WO2007000928A1 Remedy and/or preventive for chronic heart failure |
| 01/04/2007 | WO2007000924A1 Pharmaceutical composition comprising substance capable of inhibiting or promoting progranulin activity and screening method for substance capable of inhibiting or promoting progranulin activity |
| 01/04/2007 | WO2007000884A1 Prophylactic/therapeutic agent for bone/joint disease and screening method for the agent |
| 01/04/2007 | WO2007000764A2 Compositions and methods for enhancement of sexual function |
| 01/04/2007 | WO2007000056A1 Aromatase inhibitors for emergency contraception |
| 01/04/2007 | WO2007000038A1 Medicated gumstick for treatment in anti-inflammatory conditions and prophylaxis against nsaid gastropathy |
| 01/04/2007 | WO2006124630A3 Compositions and methods for enhancing the efficacy of vaccines |
| 01/04/2007 | WO2006095259A3 Biomarkers for cardiovascular side-effects induced by cox-2 inhibitory compounds |
| 01/04/2007 | WO2006063329A3 Enhanced protection against mycobacterium tuberculosis |
| 01/04/2007 | WO2006009805A3 Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors |
| 01/04/2007 | WO2005115466A8 Combinations comprising antimuscarinic agents and corticosteroids |
| 01/04/2007 | WO2005097138A3 Combinations comprising oxcarbazepine to treat affective disorders |
| 01/04/2007 | US20070004962 Cardiac support device with differential compliance |
| 01/04/2007 | US20070004807 Methods using phenethanolamine derivatives for treatment of respiratory diseases |
| 01/04/2007 | US20070004788 Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use |
| 01/04/2007 | US20070004784 Oxazole-, oxadiazole- or oxatriazole- functionalized bisarylsulfonamides inhibit the intermediate conductance, calcium activated potassium channel; sickle cell anemia and glaucoma; antiinflammatory, antiproliferative, bronchodilator agents |
| 01/04/2007 | US20070004780 Administering 2 to 8 mg per day of nontoxic insulin sensitiser rosiglitazone, and 500 mg or 850 mg of biguanide antihyperglycaemic agent; Type II diabetes |
| 01/04/2007 | US20070004756 Pharmaceutical compositions |
| 01/04/2007 | US20070004744 Prophylaxis and/or treatment of portal hypertension |
| 01/04/2007 | US20070004743 Intranasal administration of mc4-r agonists |
| 01/04/2007 | US20070004727 Use of compounds for the prevention of drug-induced cell toxicity |
| 01/04/2007 | US20070004721 Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases |
| 01/04/2007 | US20070004681 Methods for treating arthritic conditions |
| 01/04/2007 | US20070004678 Production and use of a polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes |
| 01/04/2007 | US20070004669 Mono-, di- or trifluoromethyl derivatives, e.g., 6-amino-9-(2-C-fluoromethyl- beta -D-ribofuranosyl)purine, 2'-C-(fluoromethyl)-5-methylcytidine and 2-amino-9-(2-C-fluoromethyl- beta -D-ribofuranosyl)-3,9-dihydropurin-6-thione; used to treat a hepatitis C virus infection |
| 01/04/2007 | US20070004668 Antisense permeation enhancers |
| 01/04/2007 | US20070004620 Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus |
| 01/04/2007 | US20070004008 Human ccv polypeptides |
| 01/04/2007 | US20070003630 Anti-angiogenic compositions and methods of use |
| 01/04/2007 | US20070003629 Anticancer agents; prevent forming blood vessels; removal blockage |